CytoDyn Inc. (CYDY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | -6 | - | - |
| Operating profit | $m | 11 | - | ||||||
| Net profit | $m | -140 | -174 | -211 | -80 | -50 | 4 | - | - |
| EPS reported | $ | 0.00 | - | ||||||
| Operating cashflow per share | $ | -0.01 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | -0.01 | - | ||||||
| Free cash flow | $m | -9 | - | ||||||
| Net debt | $m | 15 | - | ||||||
| Book value equity | $m | -96 | - | ||||||
| Book value per share | $ | -0.08 | - | ||||||
| Number of shares | m | 1,242.92 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 188.28 | - | ||||||
| P/B LTM | x | -4.25 | - | ||||||
| P/S LTM | x | -69.07 | - | ||||||
| P/FCF LTM | x | -46.62 | - | ||||||
| EV/EBITDA LTM | x | 49.20 | - | ||||||
| EV/Sales LTM | x | -71.68 | - | ||||||
| Earnings Yield LTM | % | +0.53% | - | ||||||
| FCF Yield | % | -2.14% | - | ||||||
| Quality | |||||||||
| ROE | % | -3.90% | - | ||||||
| ROIC | % | -45.06% | - | ||||||
| Operating margin | % | -1.91% | - | ||||||
| Gross margin | % | +0.30% | - | ||||||
| FCF/Sales | % | +148.16% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -0.32 | - | ||||||
| Net Debt/EBITDA | x | 1.79 | - | ||||||
| EBIT/Net interest | x | 2.33 | - | ||||||
| Net debt/market cap | % | +6.66% | - | ||||||
| Net debt/Equity | x | -0.16 | - | ||||||
| Gross debt/equity | x | -0.28 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free